I am an expert in tumor immunology (MD, PhD) and I am currently a Member of the Ludwig Institute for Cancer Research and co-director of the de Duve Institute. I am also Full Professor of Immunology at the Université catholique de Louvain in Brussels and I train young scientists, including PhD students, medical students and postdoctoral Fellows form all over the world. I serve as member of several national and international scientific committees and editorial boards, and I am a full member of the Belgian Royal Academy of Medicine.
I initially identified, together with Thierry Boon, the first tumor rejection antigen naturally expressed by mouse tumors. I subsequently identified a number of human tumor antigens and studied their processing. This led to the discovery of peptide splicing by the proteasome and of novel proteasome subtypes. I also described how tumors resist immune rejection by catabolizing tryptophan, through the expression of indoleamine dioxygenase (IDO) or tryptophan dioxygenase (TDO).
I am also co-founder of iTeos Therapeutics, a biotechnology company based in Gosselies (Belgium) launched in 2012 as a spin-off of Ludwig Cancer Research. Its activity consists in developing small molecule immunomodulators for cancer treatment. Its first compound, an IDO inhibitor, will soon enter clinical testing in cancer patients.
In 2016, I also started a new group at Ludwig Oxford, to develop synergies in the tumor immunology landscape, focusing on cancer vaccines. I am also Professor of tumor immunology at the University of Oxford.
I have published more than 150 scientific papers and books and given more than 100 invited lectures at international meetings. My work has been cited more than 11,000 times in the scientific literature
MD (1986) and PhD (1995), Université catholique de Louvain, Brussels, Belgium
Residencies, Ludwig Institute for Cancer Research, de Duve Institute, Université catholique de Louvain, Brussels, Belgium